Inicio>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> ADC Cytotoxin>>DC41-SMe

DC41-SMe

Catalog No.GC35818

DC41-SMe, un derivado de DC1, muestra citotoxicidad en células Ramos, Namalwa y HL60/s con IC50 que oscilan entre 18 y 25 pM. DC1, un análogo simplificado de CC-1065, es un conjugado de anticuerpos de alquiladores de ADN citotóxicos para el tratamiento específico del cáncer.

Products are for research use only. Not for human use. We do not sell to patients.

DC41-SMe Chemical Structure

Cas No.: 1354787-71-5

Tamaño Precio Disponibilidad Cantidad
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

DC41-SMe is a DC1 derivative, shows cytotoxicity in Ramos, Namalwa, and HL60/s cells with IC50s ranging from 18-25 pM. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer[1][2].

[1]. Zhao RY, et al. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. J Med Chem. 2012 Jan 26;55(2):766-82. [2]. Kovtun YV, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006 Mar 15;66(6):3214-21.

Reseñas

Review for DC41-SMe

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DC41-SMe

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.